Jaguar Health, SynWorld mutually agree to terminate license agreement

Jaguar Health and SynWorld Technologies announced that the two companies have mutually agreed to terminate the exclusive license and services agreement executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar’s Canalevia prescription drug product effective January 31, 2023. On the effective date of termination of the Canalevia Agreement, all licenses granted to SynWorld by Jaguar under the Canalevia Agreement were revoked and the rights granted thereunder reverted back to Jaguar.